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ORIGINAL ARTICLE
Effect of Chloroquine, Hydroxychloroquine, and 
Azithromycin on the Corrected QT Interval in 
Patients With SARS-CoV-2 Infection
Moussa Saleh , MD; James Gabriels , MD; David Chang , MD; Beom Soo Kim, MD; Amtul Mansoor , MD;  
Eitezaz Mahmood, MD; Parth Makker , MD; Haisam Ismail, MD; Bruce Goldner , MD; Jonathan Willner, MD;  
Stuart Beldner, MD; Raman Mitra , MD, PHD; Roy John, MBBS, PHD; Jason Chinitz, MD; Nicholas Skipitaris , MD;  
Stavros Mountantonakis, MD; Laurence M. Epstein , MD
BACKGROUND: The novel SARS-CoV-2  (severe acute respiratory syndrome coronavirus 2) is responsible for the global coronavirus 
disease 2019 pandemic. Small studies have shown a potential benefit of chloroquine/hydroxychloroquine±azithromycin for 
the treatment of coronavirus disease 2019. Use of these medications alone, or in combination, can lead to a prolongation of 
the QT interval, possibly increasing the risk of Torsade de pointes and sudden cardiac death.
METHODS: Hospitalized patients treated with chloroquine/hydroxychloroquine±azithromycin from March 1 to the 23 at 3 hospitals 
within the Northwell Health system were included in this prospective, observational study. Serial assessments of the QT interval 
were performed. The primary outcome was QT prolongation resulting in Torsade de pointes. Secondary outcomes included QT 
prolongation, the need to prematurely discontinue any of the medications due to QT prolongation, and arrhythmogenic death.
RESULTS: Two hundred one patients were treated for coronavirus disease 2019 with chloroquine/hydroxychloroquine. Ten 
patients (5.0%) received chloroquine, 191 (95.0%) received hydroxychloroquine, and 119 (59.2%) also received azithromycin. 
The primary outcome of torsade de pointes was not observed in the entire population. Baseline corrected QT interval 
intervals did not differ between patients treated with chloroquine/hydroxychloroquine (monotherapy group) versus those 
treated with combination group (chloroquine/hydroxychloroquine and azithromycin; 440.6±24.9 versus 439.9±24.7 ms, 
P=0.834). The maximum corrected QT interval during treatment was significantly longer in the combination group versus the 
monotherapy group (470.4±45.0 ms versus 453.3±37.0 ms, P=0.004). Seven patients (3.5%) required discontinuation of 
these medications due to corrected QT interval prolongation. No arrhythmogenic deaths were reported.
CONCLUSIONS: In the largest reported cohort of coronavirus disease 2019 patients to date treated with chloroquine/hydroxyc
hloroquine±azithromycin, no instances of Torsade de pointes, or arrhythmogenic death were reported. Although use of these 
medications resulted in QT prolongation, clinicians seldomly needed to discontinue therapy. Further study of the need for QT 
interval monitoring is needed before final recommendations can be made.
VISUAL OVERVIEW: A visual overview is available for this article.
Key Words: azithromycin ◼ chloroquine ◼ COVID-19 ◼ hydroxychloroquine ◼ pandemic ◼ QT prolongation
In December of 2019, reports of an unknown pneumo-nia not responsive to traditional treatments emerged in Wuhan, China. The pathogen, which came to be identi-
fied as the severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), is a novel coronavirus that is now known to 
be responsible for the coronavirus disease 2019 (COVID-
19) illness. Since then, the virus has spread internationally 
infecting ≈1 million individuals and resulting in >50 000 
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deaths. COVID-19 was declared a public health emergency 
of international concern on January 30, 20201. Although 
strong data supporting any specific therapy has been lack-
ing, several pharmacological intervention strategies have 
been proposed for the management of COVID-19 in hopes 
of decreasing morbidity and mortality related to the illness. 
One such therapy currently under study in humans is the use 
of chloroquine or hydroxychloroquine. Chloroquine, a medi-
cation commonly used to treat malaria, has been shown to 
inhibit viral infection by changing the endosomal pH that is 
required for viral-cell fusion as well as interfering with the 
glycosylation of cellular receptors of SARS-CoV.2 Compared 
with chloroquine, hydroxychloroquine has been shown in 
vitro to have higher inhibition against SARS-CoV-2.3 These 
limited studies have resulted in a surge in the use of chloro-
quine or hydroxychloroquine with and without azithromycin 
in patients requiring inpatient care for COVID-19. Although 
many are hopeful that these inexpensive and readily avail-
able medications may be the key to decreasing mortality in 
this pandemic, as of the writing of this article, no such data 
exists. A notable concern is the association of QT prolonga-
tion and Torsade de pointes (TdP) with these medications 
when individually prescribed, and the increased risk when 
they are administered together, especially in patients with 
hepatic disease or renal failure. To evaluate the arrhythmic 
safety of chloroquine/hydroxychloroquine±azithromycin, we 
conducted this prospective evaluation in adult patients hos-
pitalized with COVID-19.
METHODS
To minimize the possibility of unintentionally sharing informa-
tion that can be used to reidentify private information, a sub-
set of the data generated, and the analytical methods used for 
this study are available from the corresponding author to other 
researchers upon reasonable request. This study was approved 
by the Institutional Review Board of Northwell Health, which 
waived the requirement for individual informed consent.
From the start of the outbreak until April 4, 2020, 3180 
patients have received combination hydroxychloroquine and 
azithromycin, and 1181 patients received hydroxychloroquine 
alone for the treatment of COVID-19 in 14 hospitals of the New 
York State Northwell Health system. The present study is an 
in-depth prospective, observational study from 3 of the hospi-
tals. All hospitalized patients >18 years of age with polymerase 
chain reaction confirmed COVID-19 illness treated with chlo-
roquine/hydroxychloroquine±azithromycin were identified from 
March 1 to March 23. The decision to treat with chloroquine/
hydroxychloroquine±azithromycin was based on the clinical 
decision of the admitting physician and predescribed healthcare 
system guidelines. Healthcare system criteria for the use of 
chloroquine/hydroxychloroquine±azithromycin therapy placed 
on March 1 were as follows: confirmed Covid-19 polymerase 
chain reaction testing or high suspicion of Covid-19 with test 
pending; acute respiratory distress syndrome or severe illness 
characterized by systemic inflammatory response syndrome 
criteria; or clinician’s judgment that the patient is likely to prog-
ress to acute respiratory distress syndrome or severe illness in 
the next 6 hours. Patients not meeting the criteria for therapy 
were excluded from the study. Patients chronically on hydroxy-
chloroquine for autoimmune diseases, such as lupus, those with 
a documented hypersensitivity to any of the agents, and any 
patient that refused the therapies were excluded from the study.
Demographics, inpatient medication lists, values from the 
baseline ECGs including QRS duration, QRS morphology, and QT 
interval duration were collected on all patients before initiation of 
therapy. Inpatient medication orders were reviewed daily and any 
concomitant QT-prolonging agent usage was identified. Twice 
daily ECGs, except for patients that received a Mobile Cardiac 
Outpatient Telemetry (MCOT) Patch (BioTelemetry, Malvern, PA), 
were obtained to assess the corrected QT interval (QTc). Given 
the large number of COVID-19 patients admitted throughout the 
health system and the limited amount of telemetry beds available, 
the MCOT patches were used to monitor for both QT prolonga-
tion and for arrhythmias in patients on nontelemetry units. MCOT 
Nonstandard Abbreviations and Acronyms
COVID-19 coronavirus disease 2019
hERG  human ether-a﻿̀-go-go related gene
MCOT  Mobile Cardiac Outpatient Telemetry
SARS-CoV-2  severe acute respiratory syndrome 
coronavirus 2
TdP  torsade de pointes
WHAT IS KNOWN?
• The antimalaria drugs chloroquine and hydroxy-
chloroquine and the commonly used macrolide 
antibiotic azithromycin are all known to increase the 
corrected QT interval.
• A corrected QT interval >500 ms increases the risk 
of torsade de pointes by 2- to 3-fold. Other risk fac-
tors include drug interactions affecting drug serum 
levels, concomitant use of QT prolonging agents, 
female gender, structural heart disease, genetic 
polymorphisms, electrolyte disturbances, bradycar-
dia, and hepatic disease.
WHAT THE STUDY ADDS?
• In hospitalized COVID-19 patients, the use of 
chloroquine/hydroxychloroquine and azithromycin 
resulted in a significantly greater increase in the cor-
rected QT interval when compared with monother-
apy with either chloroquine or hydroxychloroquine.
• Although patients experienced corrected QT inter-
val prolongation, especially when combination 
therapy was used, the risk of arrhythmic death and 
torsade de pointes were not increased.
• Though the efficacy of chloroquine/
hydroxychloroquine±azithromycin in patients with 
coronavirus disease 2019 (COVID-19) is unproven, 
the arrhythmic risk appears to be low and may not 
warrant monitoring in most hospitalized patients.
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patches were preprogrammed to transmit twice daily telemetry 
strips for QT interval measurements. Telemetry or MCOT Patch 
urgent alerts were reviewed for all patients and any cardiac 
arrhythmias were documented. Premature discontinuation of any 
of the medications due to QT prolongation was also noted. All 
QT intervals obtained from an ECG or MCOT patch were manu-
ally measured by a physician on the research team. Lead II was 
utilized for the measurement of the QT interval on ECG. If the 
T-wave could not easily be measured in lead II, leads V6, or I were 
alternatively used. The end of the T-wave was defined as the tan-
gent drawn from the steepest last limb of the T-wave to its inter-
section with the baseline. If a baseline BBB was present, the J-T 
interval was measured and 120 ms was added to obtain the QT 
interval duration. Bazett formula was used to calculate the cor-
rected QT interval. Baseline QT interval measurements obtained 
from the MCOT patch were compared with that of the baseline 
ECG utilizing lead I, as the MCOT patch provides a lead I strip, 
to ensure accuracy. Serial ECGs were not obtained on MCOT 
patients to decrease staff exposure. Given the observational 
nature of the study, members of the research team measuring the 
QT interval were not blinded to the patient information or course. 
All telemetry, ECG, and MCOT patch monitoring findings, and QT 
interval measurements were adjudicated by a senior board-certi-
fied cardiac electrophysiologist and a cardiac electrophysiology 
fellow board-certified in cardiovascular disease.
OUTCOME MEASURES
The primary clinical outcome of the study was QT pro-
longation resulting in TdP. Secondary outcomes included 
QT prolongation and QT prolongation that resulted in the 
need to prematurely terminate chloroquine, hydroxychlo-
roquine, or azithromycin as well as arrhythmogenic death.
STATISTICAL ANALYSIS
As this was a prospective, observational study without a 
specific control population, only a basic statistical analy-
sis was utilized. Continuous variables were reported as 
the mean±SD and categorical variables were reported 
as numerical values and percentages. The Welch t test 
was used to compare ECG changes during treatment 
with the patients’ baseline ECGs. A multivariable linear 
regression analysis was performed to test the impact of 
monotherapy versus combination therapy, and gender 
along with the interaction between the 2 on the outcome 
of change in QTc. Fisher exact test was used to compare 
the number of patients with a QTc >500 ms in the mono-
therapy versus combination groups. The SAS Version 9.4 
(Cary, NC) statistical software was used for the analysis.
RESULTS
Between March 1st and March 23, there were 201 
patients that were treated for COVID-19 with either 
chloroquine or hydroxychloroquine at 3 hospitals in the 
Northwell Health system. A minority of these patients 
(10, 5.0%) received chloroquine. Of the 201 patients on 
either chloroquine or hydroxychloroquine, 119 (59.2%) 
also received azithromycin. The treatment regimens for 
these medications were as follows: chloroquine 500 mg 
by mouth twice daily for 1 day followed by 500 mg by 
mouth once daily for 4 days, hydroxychloroquine 400 mg 
by mouth twice daily for 1 day followed by 200 mg by 
mouth twice daily for 4 days, and azithromycin 500 mg 
by mouth or intravenous daily for 5 days. The average 
age of the cohort was 58.5±9.1 and 115 (57.2%) were 
male patients. Complete demographics are displayed in 
Table 1, and details regarding inpatient medication usage 
are outlined in Table 2.
A baseline ECG was performed before initiating ther-
apy for COVID-19 for all patients. A majority of patients 
were in sinus rhythm (177, 88.1%) with baseline heart rate 
of 80.5±17.7 beats per minute. The mean QRS duration 
for the population at baseline was 92.8±19.0 ms with 46 
patients (22.9%) having an intraventricular conduction 
delay, incomplete, or complete right bundle branch block, 
left bundle branch block, or a ventricular paced rhythm.
Serial ECGs were used to monitor QTc intervals for 84 
patients, and 117 patients (58.2%) were monitored with 
an MCOT patch. The baseline QTc for the entire cohort 
was 439.5±24.8 ms and 8 patients (4.0%) had a base-
line QTc >500 ms. The average maximum QTc during 
treatment for the entire cohort was 463.3±42.6 ms and 
the post-treatment QTc was 454.8±40.1 ms. The aver-
age increase in the QTc after the 5-day course treatment 
was 19.33±42.1 ms (Table 3).
The baseline QTc intervals for the monotherapy group 
were 438.9±25.0 ms and for the combination therapy 
group was 439.9±24.7 ms (P=0.79). The maximum QTc 
during treatment was significantly shorter in patients 
Table 1. Baseline Demographics
Characteristic N=201
Age, y 58.5±9.1
Male sex 115 (57.2%)
Body mass index, kg/m2 28.2±2.8
Hypertension 121 (60.2%)
Hyperlipidemia 84 (41.8%)
Diabetes mellitus 65 (32.3%)
Atrial fibrillation 14 (7.0%)
Coronary artery disease 23 (11.4%)
Chronic obstructive pulmonary disease/asthma 30 (14.9%)
Chronic kidney disease ≥stage III 10 (5.0%)
Ejection fraction, % 61.9±5.7*
Heart failure 15 (7.5%)
Prior permanent pacemaker/automated internal 
cardioverter-defibrillator
3 (1.5%)
Values listed are represented as means±SDs for continuous variables and 
numbers (percentages) for categorical variables.
*Data for ejection fraction, including echocardiograms performed within the 
last 6 months, was only available for 41 patients (20.4%).
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treated with chloroquine/hydroxychloroquine monother-
apy when compared with patients treated with a combi-
nation of either of these medications and azithromycin 
(453.3±37.0 versus 470.4±45.0 ms, P=0.004; Table 4). 
Additionally, there were no statistically significant effects 
of gender (P=0.091) or an interaction between the effects 
of gender and medications on the difference between 
the Maximum QTc and the baseline QTc (P=0.93). The 
overall trajectory of QTc change is represented in Fig-
ure 1. The number of patients with a peak QTc >500 
ms was 7 (8.6%) in the monotherapy group versus 11 
(9.2%) in the combination therapy group (P=1.00) (Fig-
ure 2). Further details regarding these patients can be 
found in Table 5.
In addition to QT prolongation, there were 17 instances 
of new-onset atrial fibrillation that were discovered either 
on telemetry or an MCOT patch. Seven patients had 
monomorphic nonsustained ventricular tachycardia, and 
1 patient had sustained, hemodynamically stable, mono-
morphic ventricular tachycardia in the setting of likely viral 
myocarditis (Table 6). The primary outcome of QT pro-
longation leading to TdP was not observed in the entire 
population. Arrhythmogenic death was also not observed 
in the entire cohort. The secondary outcome involving the 
need to discontinue hydroxychloroquine due to QT prolon-
gation occurred in 7 (3.5%) patients with average QTc of 
504.4±39.5 ms. Details regarding these patients can be 
found in Tables 7 and 8. The trajectory of their QTc change 
is represented in Figure 3. A complete list of arrhythmic 
events and interventions is listed in Table 9. Following 
the development and implementation of the Northwell 
flow chart to minimize TdP in COVID-19 inpatients on 
hydroxychloroquine/azithromycin, lidocaine was used to 
facilitate continuation of hydroxychloroquine in 2 other 
patients.4 The first patient’s QTc increased from baseline 
of 458 to 594 ms after receiving hydroxychloroquine 400 
mg for 2 doses followed by 200 mg for 3 doses and 2 
doses of intravenous azithromycin 500 mg. The patient 
was given a single dose of intravenous lidocaine 100 mg, 
which improved QTc to 479 ms. Azithromycin was discon-
tinued at this time while hydroxychloroquine 200 mg twice 
daily was continued for the full 5-day course. Of note, this 
patient was given a dose of intravenous amiodarone 150 
mg 2 days before reaching the peak QTc during a rapid 
Table 2.  Inpatient Medication Usage
Medication N=201
Hydroxychloroquine 191 (95.0%)
Chloroquine 10 (5.0%)
Azithromycin
 Total 119 (59.2%)
 1 dose 26 (12.9%)
 2–4 doses 46 (22.9%)
 5 doses 47 (23.4%)
Beta blocker/nondihydropyridine calcium channel 
blocker
34 (16.9%)
Antiarrhythmic medications 3 (1.5%)
Antiplatelets 28 (13.9%)
Oral anticoagulants 12 (6.0%)
Other QT prolonging agents* 81 (40.3%)
Values listed are represented as numbers (percentages) for categorical 
variables.
*Albuterol, alprazolam, amiodarone, amitriptyline, aripiprazole, citalopram, 
chlorpromazine, ciprofloxacin, clozapine, cyclobenzaprine, dexmedetomidine, 
diphenhydramine, donepezil, dronedarone, escitalopram, flecainide, furosemide, 
fluconazole, haloperidol, levetiracetam, levofloxacin, lithium, metoclopramide, 
mirtazapine, norepinephrine, olanzapine, ondansetron, pantoprazole, 
phenobarbital, quetiapine, risperidone, venlafaxine, ziprasidone
Table 3.  Electrocardiographic Characteristics of the 
Study Cohort
ECG Characteristics N=201 P Value
Sinus rhythm 177 (88.1%)  
Atrial fibrillation/flutter 14 (7.0%)  
Baseline heart rate 80.5±17.7  
Baseline QRS 92.8±19.0  
Baseline QTc 439.5±24.8 –
Max QTc 463.3±42.6 <0.05
Max QTc—baseline QTc 23.8±35.5  
QRS duration 94.9±19.2  
QRS duration—baseline QRS 2.2±9.6  
Final QTc 454.8±40.1 <0.05
Final QTc—baseline QTc 15.4±35.4  
QRS duration 95.9±20.2  
QRS duration—baseline QRS 3.0±10.5  
Values listed are represented as means±SDs for continuous variables. P 
values to assess ECG changes to the baseline ECG. QTc indicates corrected 
QT interval.
Table 4.  Comparison of QTc Measurement in HCQ Cohort 
vs HCQ and AZM Cohort
QTc 
Measurements 
in Patients 
Treated With 
HCQ/CQ 
(N=82)
QTc 
Measurements 
in Patients 
Treated With 
HCQ/CQ and 
AZM (N=119) P Value
Baseline QTc 438.9±25.0 439.9±24.7 0.79
Baseline QRS 92.0±15.5 93.0±19.8 0.85
Max QTc 453.3±37.0 470.4±45.0 0.004
Max QTc—baseline QTc 14.4±25.0 30.4±40.2 <0.001
QRS duration 91.9±15.6 95.6±20.0 0.48
QRS duration—baseline QRS −0.1±6.14 2.7±10.2 0.21
QTc >500 (no. of patients) 7 11 1.00
Final QTc 444.7±34.2 462.0±42.4 0.002
Final QTc—baseline QTc 6.0±25.0 22.0±40.1 <0.001
QRS duration 91.9±13.1 96.7±21.4 0.30
QRS duration—baseline QRS −0.2±8.5 3.7±10.8 0.18
Values listed are represented as means±SDs for continuous variables. 
AZM indicates azithromycin; CQ, chloroquine; HCQ, hydroxychloroquine; QTc, 
corrected QT; and Max, maximum.
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response for atrial fibrillation and acute hypoxic respira-
tory failure that required intubation. Two days after finish-
ing the course of hydroxychloroquine, the QTc prolonged 
to 601 ms. Of note, the patient was receiving intravenous 
furosemide and pantoprazole, which may have contrib-
uted to the QTc prolongation. The patient appropriately 
responded to another dose of intravenous lidocaine. The 
subsequent QTc improved to 551 mg and normalized to 
<500 ms on subsequent ECGs. The second patient’s QTc 
increased from 456 ms to 620 ms after receiving 1 dose 
of hydroxychloroquine. She was given a dose of intrave-
nous lidocaine 100 mg, which improved the QTc to 550 
ms. This patient went on to complete the 5-day course of 
hydroxychloroquine with no further prolongation of QTc.
DISCUSSION
The main findings of this study were (1) the use of chlo-
roquine/hydroxychloroquine and azithromycin led to a 
significantly greater increase in the corrected QT interval 
when compared to monotherapy with either chloroquine 
or hydroxychloroquine, (2) prolongation of the QTc only 
led to premature discontinuation of these medications in 
3.5% of patients, and (3) there were no instances of the 
primary end point of TdP in the entire cohort.
The SARS-CoV-2 virus is an enveloped β coronavirus 
that is thought to have transmitted to humans via zoo-
notic transfer.5,6 Virus binding and cell entry are facilitated 
by a type I membrane spike glycoprotein on the surface 
of the SARS-CoV-2 virus that binds to ACE (angioten-
sin-converting enzyme)-2 receptors found in the upper 
and lower human respiratory tract.7,8 The SARS-CoV-2 
virus emerged from China in December of 2019 and has 
subsequently resulted in an explosion of proposed thera-
pies for treating the virus. Among these therapies, chloro-
quine/hydroxychloroquine with and without azithromycin 
are now commonly being used, following studies that 
showed virus-cell fusion inhibition.2,3 To date, there has 
been little actionable clinical data on the efficacy of using 
these medications in humans infected with the SARS-
CoV-2 virus. In a 2005 cohort of 23 hospitalized patients 
with SARS-CoV, To et al9 reported a direct correlation 
between viral load and increasing age, suggesting an 
increased expression of ACE-2 receptors with age may 
result in higher viral loads. The relationship between viral 
load and disease severity, however, was not addressed. 
Viral load was noted to peak during the first week of 
Figure 1. Trajectory of corrected QT 
interval (QTc) change in 201 patients 
receiving hydroxychloroquine±azith
romycin.
Change in QTc was seen starting on day 
2 of therapy with max QTc being reached 
on day 4 by the majority of patients.
Figure 2. Percentage of patients with 
increase in corrected QT interval 
(QTc) for HCQ monotherapy vs 
hydroxychloroquine and azithromycin 
combination therapy.
The majority of patients in both groups 
had an increase in QTc of 0–20 ms. 
Higher percentage of patients treated with 
the combination therapy had an increase 
in QTc of 40–60 ms and >60 ms.
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illness and steadily declined over the following week.10 
Subsequently, a 30-patient study in mildly symptomatic 
patients showed no benefit of chloroquine with regards 
to clearance of viral load, time to temperature normal-
ization, and disease progression.11 Major trials evaluating 
clinical efficacy of this combination therapy are currently 
underway globally.
A major concern with the use of this therapy has 
been the risk of QT prolongation and TdP. TdP is a form 
of polymorphic ventricular tachycardia that occurs in 
the setting of QT prolongation that is characterized by 
gradual twisting and amplitude change of the QRS com-
plexes around an isoelectric line that either spontane-
ously terminates or degenerates to ventricular fibrillation 
in about 10% of cases.12,13 Traditionally, QT-prolonging 
agents have been avoided in individuals with a QTc >500 
ms due to a 2-fold to 3-fold increase in risk for TdP with 
such intervals.14–16 Most drugs cause QT prolongation by 
blocking the human ether-a﻿̀-go-go related gene (hERG) 
potassium channel, the voltage-gated ion channel that 
mediates the rapid component of the delayed rectifier 
potassium current, IKr, resulting in lengthening of both 
ventricular repolarizations, and the duration of the ven-
tricular action potential.17 In a similar fashion, this can 
result in the reactivation of calcium influx causing trig-
gered early afterdepolarization activity. A well-timed 
early afterdepolarization trigger, in the presence of a 
prolonged QT interval, can result in TdP.18
Other risk factors for TdP include drug interactions 
affecting drug serum levels, concomitant use of QT-
prolonging agents, female sex, structural heart disease, 
genetic polymorphisms, electrolyte disturbances, brady-
cardia, and hepatic disease. Such risk factors result in 
repolarization reserve reduction.18,19 Although the QTc is 
sensitive for predicting TdP, it is not specific. The rela-
tionship between QT prolongation and TdP is not linear 
as drugs that prolong the QT have not consistently been 
associated with cardiac arrhythmias. Incidences of sudden 
cardiac death occurring in the absence of QT prolongation 
on surface ECG have also been reported. Of all the QT 
prolonging drugs, antiarrhythmics have the highest risk of 
TdP with an incidence of 1% to 5%, whereas the risk from 
noncardiovascular drugs is much lower at 0.001%.13
Four hundred million courses of antimalarial drugs 
are annually used around the world.20 Antimalarial drugs 
are well known for their potential cardiac toxicity and QT 
prolongation effects. Of the drugs used, quinidine and 
halofantrine are the most likely to cause QT prolonga-
tion and TdP.21–23 Chloroquine’s reported risk of sudden 
cardiac death is limited to cases of hypotension due to 
vasodilation and negative inotropy resulting from rapid 
parenteral administration of the medication or situations of 
self-inflicted overdose.24 The risk of QT prolongation and 
Table 5.  Characteristics of Patients With QTc >500 ms
QTc >500 ms in 
Patients Treated 
With HCQ/CQ 
(n=7)
QTc >500 ms in 
Patients Treated 
With HCQ/CQ and 
AZM (n=11) P Value
Female sex 3 3 0.63
Structural heart disease 1 0 0.39
Cirrhosis 0 0 1.00
Baseline QTc, ms 456.5±21.2 449.7±24.4 0.578
Receiving other QT-
prolonging medications
3 7 0.63
AZM indicates azithromycin; CQ, chloroquine; HCQ, hydroxychloroquine; and 
QTc, corrected QT.
Table 6.  Characteristics of Patients With Monomorphic Ventricular Arrhythmias
Age/
sex
Medication 
Regimen
Arrhythmia 
Duration, s
Arrhythmia 
Rate (beats 
per minute) CAD HF
EF  
(%)
Evidence of 
Ischemia/ 
Myocarditis
HS Trop, 
ng/L
K, 
mmol/L
Mg, mg/
dL
Ca2+, 
mg/dL
Clinical 
Status
Outcome 
(Length of Stay 
in Days)
49M HCQ 240 200 0 1 40 Myocarditis 4407 4.8 2.1 8.8 ICU/
ventilator
Deceased* (5)
58M HCQ+AZM 5.6 180 0 1 15 No 57 3.5 2.0 8.7 Room air Discharged (2)
65M HCQ+AZM 12 195 0 0 58 No 28 3.7 2.0 9.4 Nasal 
cannula
Discharged (14)
85M HCQ+AZM 10 190 0 0 … No 44 4.0 2.9 8.4 ICU/
ventilator
Deceased* (22)
56F HCQ+AZM 5 170 0 0 … No 67 5.5 2.7 10.1 ICU/
ventilator
Admitted (24)
88F HCQ+AZM 20 210 0 0 … No 50 3.7 2.5 8.4 Nasal 
cannula
Discharged (13)
72F† HCQ 3.6 180 0 0 … No 23 4.2 1.8 10.1 Nasal 
cannula
Discharged (11)
69M† HCQ+AZM 1.6 150 0 0 … No 15 3.5 2.1 8.7 Nasal 
cannula
Discharged (6)
AZM indicates azithromycin; Ca2+, calcium; CAD, coronary artery disease; EF, ejection fraction; F, female; HCQ, hydroxychloroquine; HF, heart failure; HS, high 
sensitivity; ICU, intensive care unit; K, potassium; M, male; MCOT, Mobile Cardiac Outpatient Telemetry; Mg, magnesium; and Trop, troponin.
*The cause of death for these patients was multi-system organ failure.
†These patients were monitored with MCOTs. The remainder were monitored with 12-lead electrocardiograms.
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TdP with hydroxychloroquine is limited to a series of case 
reports in patients with either chronic use or overdose.25–27
The reported effects of chloroquine and hydroxy-
chloroquine on the QT interval may also be significantly 
affected by the course of acute malaria. Increased sym-
pathetic tone due to fevers, anxiety, and anorexia at the 
onset of illness results in QT interval shortening. As 
patients recover with medical therapy, QT interval nor-
malizes. QT interval normalization on day 3 of therapy, 
which coincides with peak drug level, may have been 
mistakenly attributed to the drugs.24 Furthermore, the 
Bazett formula, used in malaria studies, overestimates 
the number of patients with QT prolongation and could 
have contributed to the reported QT prolonging effects 
of chloroquine and hydroxychloroquine.28
Azithromycin, a widely utilized macrolide antibiotic, has 
been reported to increase QT interval and incidence of 
TdP.29–35 In a 2012 retrospective observational study, 5 
days of therapy with azithromycin was found to have a 
small but statistically significant increase in cardiovascular 
death driven by sudden cardiac death. This effect did not 
persist after the treatment was stopped.36 The proar-
rhythmic mechanism of azithromycin is thought to be due 
to the drug’s ability to increase cardiac sodium current 
and promote intracellular sodium loading.37 However, 
data are lacking to show that the increased risk of death 
with azithromycin is a result of QT prolongation and TdT. 
Moreover, azithromycin and chloroquine combination 
therapy has been used for the protection against malaria 
and sexually transmitted infections in pregnant women 
with no reports of syncope or sudden cardiac death.38
Our study revealed that in the entire cohort treated 
with chloroquine/hydroxychloroquine or azithromycin, 
the increase in QTc to its peak (max QTc), and post-
treatment QTc (final QTc) were statistically significant 
(P<0.05; Table 3). When further broken down to 2 treat-
ment cohorts as shown in Table 4, the group treated 
with the combination therapy had longer Max and Final 
QTc intervals compared with the monotherapy group 
(P=0.004 and P=0.002, respectively). However, it is 
important to highlight that no patient had QTc prolonga-
tion that resulted in TdP. Seven patients (3.5%) needed 
to discontinue the medications due to QTc prolongation. 
Two additional patients were treated with intravenous 
lidocaine that shortened the QTc allowing for continua-
tion of hydroxychloroquine. The decision to discontinue 
therapy was variable based on provider personal thresh-
old and comfort. This explains why some patients with 
similarly prolonged QTc intervals continued therapy.
As the volume of hospitalized COVID-19 patients 
has increased throughout our health system, our ability 
to monitor every patient receiving combination therapy 
became limited due to the finite amount of telemetry beds 
available. The use of MCOT patch monitors allowed us 
to expand remote monitoring of cardiac arrhythmias and 
QT prolongation in patients not on traditional telemetry. 
Table 7. Proportion of Patients With Max QTc That 
Continued vs Discontinued Medical Therapy With 
HCQ±AZM
Max QTc, ms
Total Patients on 
HCQ±AZM With QTc  
>500 ms
Number of Patients 
Whose HCQ±AZM  
Was Discontinued  
Due to QTc >500 ms
500–520 8 2
520–540 2 0
540–560 3 1
560–580 2 1
580–600 2 2
>600 1 1
AZM indicates azithromycin; HCQ, hydroxychloroquine; and QTc, corrected QT 
interval.
Table 8.  Characteristics of Patients With Discontinued HCQ±AZM due to QT Prolongation
Age/
Sex
Medication 
Regimen
Baseline 
QTc
Max 
QTc
Other QT 
Prolonging 
Meds CAD HF EF, %
Evidence of 
Ischemia/ 
Myocarditis
HS Trop, 
ng/L
K, 
mmol/L
Mg, mg/
dL
Ca2+, mg/
dL
Clinical  
Status
Outcome 
(Length of Stay 
in Days)
71M HCQ+AZM 410 546 Amiodarone 1 0 … No 29 5.0 2.5 9.2 ICU/ventilator Deceased* (9)
47F HCQ 442 483 Haloperidol, 
Clozapine
0 0 … No 16 3.7 1.9 8.6 Room air Discharged (11)
49M HCQ+AZM 471 617 … 0 0 … No 11 3.7 2.8 9.2 ICU/ventilator Admitted (25)
67M HCQ+AZM 434 501 Dronedarone, 
Pantoprazole
0 0 … No … 3.7 2.3 8.7 Nasal cannula Discharged (10)
83F HCQ+AZM 444 588 … 1 1 30 No† 
(Takotsubo)
400 4.0 2.7 9.1 ICU/ventilator Deceased* (22)
45M HCQ+AZM 458 572 … 0 0 … No 13 4.2 2.4 9.1 ICU/ventilator Admitted (24)
56M‡ HCQ 469 565 Pantoprazole 0 0 … No 16 3.9 2.2 8.8 Nonrebreather Discharged (14)
AZM indicates azithromycin; Ca2+, calcium; CAD, coronary artery disease; EF, ejection fraction; F, female; HCQ, hydroxychloroquine; HF, heart failure; HS, high 
sensitivity; ICU, intensive care unit; K, potassium; M, male; MCOT, Mobile Cardiac Outpatient Telemetry; Mg, magnesium; QTc, corrected QT interval; and Trop, troponin.
*The cause of death was hypoxic respiratory failure and sepsis for both patients.
†A transthoracic echocardiogram performed during the admission showed apical and mid left ventricular hypokinesis with sparing of the basal segments.
‡This was the only patient that monitored with an MCOT. The remainder were monitored with 12-lead electrocardiograms.
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The MCOT monitor is Food and Drug Administration–
approved for the measurement, analysis, and reporting of 
QT intervals. The use of the monitor resulted in a reduction 
of exposures and personal protective equipment use by 
healthcare workers as the need for serial ECGs to monitor 
the QT interval was eliminated in this subset of patients.
Further investigation of this combination therapy is 
needed, especially given the lack of randomized con-
trolled trials showing efficacy. Based on our experi-
ence, although patients experience QTc prolongation, 
especially when combination therapy is used, the risk 
of arrhythmic death or TdT were not increased. Further-
more, to date, a total of 3180 patients have received 
combination hydroxychloroquine and azithromycin, 
and 1181 patients received hydroxychloroquine alone 
for the treatment of COVID-19 in our healthcare sys-
tem. There continues to be no reports of TdT in those 
patients. In short, the use of this combination therapy 
for a period of 5 days may not warrant monitoring for 
cardiac arrhythmias in most patients. Our Infection dis-
ease team is no longer recommending the addition of 
azithromycin. Coupled with the findings in this study, we 
have simplified our approach to monitoring patients on 
therapy. If the baseline QTc is ≤500 ms (550 if bundle 
branch block or QRS duration >120 ms) no monitoring 
or serial ECGs will be required. If the baseline QTc is 
>500 ms (550 if bundle branch block or QRS duration 
>120 ms) on telemetry or MCOTs, no serial ECGs will 
be utilized for arrhythmia and QTc monitoring. We will be 
performing a prospective analysis of this approach.
Limitations
The main limitation of this study is the absence of a 
control cohort of patients with COVID-19 infections 
that were not treated with any of these medications. 
Although this would have provided a stronger analy-
sis, nearly every hospitalized patient with COVID-19 
received ≥1 of these medications during the course of 
their admission during this study period. The number of 
patients with underlying cardiac disease in the study is 
small, potentially limiting generalizability to that popu-
lation. The study is subject to the same limitations as 
other observational studies. Although baseline QT inter-
val readings on MCOT were correlated to the baseline 
ECGs, subsequent QT intervals in the MCOT subset 
obtained while on therapy were not. This fact and the 
difference in filtering in MCOT patches versus traditional 
12-lead ECG are a limitation. Over 4000 patients across 
the 17 hospitals in the Northwell Health system have 
received one or both therapies as of April 4, 2020 with 
no reported instances of TdT. This statistic, although very 
encouraging, may be subject to reporting bias. Lastly, 
our cohort of 201 patients, from the initial phases of 
this pandemic, represents a small fraction of the total 
patients we have treated. Further work is needed to con-
firm our findings in an even larger group of patients.
Conclusions
This is the largest reported cohort to date of patients with 
COVID-19 that were treated with chloroquine/hydroxy-
chloroquine with and without azithromycin. We observed 
a marked increase in the QT intervals of these patients 
during treatment, that was more pronounced in patients 
treated with combination therapy. Despite this increase, 
very few patients had the medications discontinued pre-
maturely due to QT prolongation. Most importantly, there 
were no cases of torsade de pointes or arrhythmic death 
in the entire population. Further study of the need for QT 
interval monitoring is needed before final recommenda-
tions can be made.
ARTICLE INFORMATION
Received April 5, 2020; accepted April 28, 2020.
Affiliations
Division of Electrophysiology, Department of Cardiology, North Shore University 
Hospital, Northwell Health, Manhasset, NY (M.S., J.G., D.C., B.S.K., A.M., E.M., 
Figure 3. Trajectory of corrected QT interval (QTc) changes 
for patients whose hydroxychloroquine (HCQ)±azithromycin 
(AZM) was discontinued due to QT prolongation (n=7).
The majority of the patients that had their HCQ±AZM therapy 
discontinued reached a max QTc >500 ms. Decision to discontinue 
therapy was based on clinician preference.
Table 9.  Arrhythmic Events and Interventions Due to QTc 
Prolongation
Arrhythmic Events and Interventions N=201
New-onset atrial fibrillation 17 (8.5%)
Nonsustained, monomorphic ventricular tachycardia 7 (3.5%)
Sustained, monomorphic ventricular tachycardia 1 (0.5%)
Torsade de pointes 0
Arrhythmogenic death 0
Use of lidocaine for QTc >500 ms 2 (0.9%)
Hydroxychloroquine±azithromycin discontinued due to 
QTc prolongation*
7 (3.5%)
QTc indicates corrected QT interval.
*Values listed are represented as numbers (percentages) for categorical 
variables.
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